bazedoxifene has been researched along with raloxifene hydrochloride in 41 studies
| Studies (bazedoxifene) | Trials (bazedoxifene) | Recent Studies (post-2010) (bazedoxifene) | Studies (raloxifene hydrochloride) | Trials (raloxifene hydrochloride) | Recent Studies (post-2010) (raloxifene hydrochloride) |
|---|---|---|---|---|---|
| 307 | 69 | 249 | 2,818 | 481 | 810 |
| Protein | Taxonomy | bazedoxifene (IC50) | raloxifene hydrochloride (IC50) |
|---|---|---|---|
| Estrogen receptor | Homo sapiens (human) | 0.0053 | |
| Gastric inhibitory polypeptide receptor | Homo sapiens (human) | 0.0004 | |
| Estrogen receptor beta | Homo sapiens (human) | 0.1297 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (12.20) | 29.6817 |
| 2010's | 32 (78.05) | 24.3611 |
| 2020's | 4 (9.76) | 2.80 |
| Authors | Studies |
|---|---|
| Crabtree, JS; Harris, HA; Komm, BS; Peano, BJ; Winneker, RC | 1 |
| Bobula, J; Lips, P; van Schoor, NM; Yu, H | 1 |
| Constantine, G; Gallagher, JC; Kagan, R; Lindsay, R; Pickar, JH | 1 |
| de Villiers, TJ | 1 |
| Lewiecki, EM | 1 |
| Bodine, PV; Chang, KC; Komm, BS; Nagpal, S; Wang, Y | 1 |
| Biserni, A; Caruso, D; Ciana, P; Horner, D; Komm, B; Maggi, A; Ramachandran, B; Rando, G | 1 |
| Adachi, JD; Brown, JP; Chesnut, CH; Chines, AA; Christiansen, C; Constantine, GD; Fernandes, CE; Kung, AW; Levine, AB; Palacios, S | 1 |
| Schmidt, C | 1 |
| Archer, DF | 1 |
| Bachmann, G; Constantine, GD; Crosby, U; Feldman, RA; Ronkin, S | 1 |
| Palacios, S | 1 |
| Lello, S | 1 |
| Iba, K; Takada, J; Yamashita, T | 1 |
| Lušin, TT; Mrhar, A; Peterlin-Mašič, L; Tomašić, T; Trontelj, J | 1 |
| Hadji, P | 1 |
| Ben Sedrine, W; Hiligsmann, M; Reginster, JY | 1 |
| Han, SJ; Liu, S; Smith, CL | 1 |
| Chines, A; Kaufman, JM; Palacios, S; Silverman, S; Sutradhar, S | 1 |
| Ferriani, RA; Figueiredo, JB; Lara, LA; Martins, WP; Nastri, CO; Rosa-E-Silva, AC | 1 |
| Pinkerton, JV; Stanczyk, FZ | 1 |
| Kanis, JA; Kim, K; Luo, X; Sutradhar, S; Svedbom, A | 1 |
| Pinkerton, JV; Thomas, S | 1 |
| Jou, D; Kumari, V; Li, C; Li, H; Lin, J; Lin, L; Xiao, H | 1 |
| Bolton, JL; Chandrasena, RE; Choi, J; Hemachandra, LP; Michalsen, BT; Patel, H; Piyankarage, SC; Scism, RA; Siklos, MI; Thatcher, GR; Thayer, EN; Wang, S; Wang, Y; Xiong, R | 1 |
| Della Torre, S; Eva, C; Fontana, R; Longo, A; Maggi, AC; Meda, C | 1 |
| Beaudart, C; Bruyere, O; Dardenne, N; Emonts, P; Neuprez, A; Reginster, JY | 1 |
| Komm, BS; Pickar, JH | 1 |
| Abramowitch, S; Knight, K; Liang, R; Moalli, PA; Nolfi, A | 1 |
| Chaki, O | 1 |
| Arias, L; Komm, BS; Mirkin, S; Palacios, S; Pan, K; Williams, R | 1 |
| Kobayashi, T; Matsumoto, M; Miyamoto, K; Miyamoto, T; Morita, M; Nakamura, M; Oike, T; Sato, Y; Tando, T; Watanabe, R | 1 |
| Lovre, D; Mauvais-Jarvis, F; Xu, B | 1 |
| Kajta, M; Lason, W; Litwa, E; Rzemieniec, J; Wnuk, A | 1 |
| Brown, M; Buchwalter, G; Carlson, KE; Chandarlapaty, S; Dharmarajan, V; Fanning, SW; Fowler, CE; Greene, GL; Griffin, PR; Han, R; Hosfield, DJ; Houtman, R; Jeselsohn, R; Karimi, M; Katzenellenbogen, JA; Lainé, M; Martin, TA; Mayne, CG; Nettles, KW; Nowak, J; Nwachukwu, JC; Shen, Y; Tajkhorshid, E; Toy, W | 1 |
| Conner, EA; Pinkerton, JV | 1 |
| Bloom, RA; Laurenson, JP; Pinto, CL | 1 |
| Hara, T; Hijikata, Y; Matsubara, Y; Watanabe, N | 1 |
| Hattori, Y; Hori, T; Hosokawa, Y; Kozawa, O; Matsushima-Nishiwaki, R; Tachi, J; Yamada, N | 1 |
| Adhikari, N; Bhattacharjee, M; Gupta, D; Pamnani, S; Panda, A; Rizvi, Z; Shehzad, S; Sijwali, PS; Sudhakar, R | 1 |
| Jain, SK; Kaur, R; Kaur, S; Kumar, M; Narendra, G; Raju, B; Sapra, B; Silakari, O; Singh, PK; Thakur, S; Tung, GK; Verma, H | 1 |
13 review(s) available for bazedoxifene and raloxifene hydrochloride
| Article | Year |
|---|---|
Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women.
Topics: Cardiovascular Diseases; Female; Humans; Indoles; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism | 2009 |
Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Drug Therapy, Combination; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Piperidines; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Vitamin D; Women's Health | 2009 |
[Selective estrogen receptor modulators: focus on bazedoxifene].
Topics: Female; Humans; Indoles; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2011 |
[Diagnostic imaging of treatment in osteoporosis: SERM].
Topics: Absorptiometry, Photon; Bone and Bones; Bone Density; Female; Hip Fractures; Humans; Indoles; Osteoporosis; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Tomography, X-Ray Computed | 2011 |
The evolution of selective estrogen receptor modulators in osteoporosis therapy.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Endometrial Neoplasms; Female; Fractures, Bone; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Tetrahydronaphthalenes | 2012 |
Hormone therapy for sexual function in perimenopausal and postmenopausal women.
Topics: Drug Therapy, Combination; Estrogens; Female; Humans; Indoles; Middle Aged; Norpregnenes; Perimenopause; Postmenopause; Progesterone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Sexual Dysfunction, Physiological | 2013 |
Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
Topics: Atrophy; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Indoles; Pelvic Organ Prolapse; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Treatment Outcome; Vagina; Vaginal Diseases; Vulva; Vulvar Diseases | 2014 |
Use of SERMs for treatment in postmenopausal women.
Topics: Breast Neoplasms; Clinical Trials as Topic; Dyspareunia; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Toremifene | 2014 |
Efficacy and safety of currently marketed anti-osteoporosis medications.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Indoles; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thiophenes | 2014 |
Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Topics: Animals; Breast; Breast Neoplasms; Drug Therapy, Combination; Estradiol; Estrogen Antagonists; Estrogens; Estrogens, Conjugated (USP); Female; Fulvestrant; Humans; Indoles; Osteoporosis; Postmenopause; Protective Factors; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene | 2015 |
The effect of selective estrogen receptor modulators on type 2 diabetes onset in women: Basic and clinical insights.
Topics: Aging; Animals; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Humans; Indoles; Insulin Resistance; Models, Biological; Obesity; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2017 |
Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators.
Topics: Adult; Aged; Atrophy; Breast Neoplasms; Estrogens, Conjugated (USP); Female; Female Urogenital Diseases; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Vagina | 2019 |
Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
Topics: Antibodies, Monoclonal; Bias; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Femur Neck; Fractures, Spontaneous; Hip; Humans; Indoles; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Parathyroid Hormone-Related Protein; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Spinal Fractures; Teriparatide; Thiophenes; Watchful Waiting | 2021 |
6 trial(s) available for bazedoxifene and raloxifene hydrochloride
| Article | Year |
|---|---|
Cross-geographic region differences in quality of life in women with and without vertebral fracture.
Topics: Aged; Body Mass Index; Bone Density Conservation Agents; Epidemiologic Methods; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Psychometrics; Quality of Life; Raloxifene Hydrochloride; Spinal Fractures | 2009 |
Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.
Topics: Absorptiometry, Photon; Adult; Aged; Bone Density; Collagen Type I; Dose-Response Relationship, Drug; Double-Blind Method; Estrogens; Estrogens, Conjugated (USP); Female; Hip Joint; Humans; Indoles; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome | 2009 |
Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Double-Blind Method; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome | 2010 |
Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial.
Topics: Bone and Bones; Bone Density Conservation Agents; Female; Hot Flashes; Humans; Indoles; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2011 |
An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®.
Topics: Aged; Aged, 80 and over; Algorithms; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indoles; Kaplan-Meier Estimate; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Risk Assessment; Spinal Fractures; Treatment Outcome | 2013 |
Efficacy and tolerability of bazedoxifene in Mexican women with osteoporosis: a subgroup analysis of a randomized phase 3 trial.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Double-Blind Method; Female; Humans; Indoles; Mexico; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride; Treatment Outcome | 2016 |
22 other study(ies) available for bazedoxifene and raloxifene hydrochloride
| Article | Year |
|---|---|
Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland.
Topics: Amphiregulin; Animals; Dose-Response Relationship, Drug; EGF Family of Proteins; Estrogens, Conjugated (USP); Female; Glycoproteins; Indoles; Intercellular Signaling Peptides and Proteins; Mammary Glands, Animal; Mice; Mice, Inbred C57BL; Organ Size; Polymerase Chain Reaction; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Uterus | 2009 |
Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogens, Conjugated (USP); Female; Gene Expression; Gene Expression Profiling; Humans; Indoles; Oligonucleotide Array Sequence Analysis; Pyrrolidines; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Signal Transduction; Tetrahydronaphthalenes; Up-Regulation | 2010 |
An innovative method to classify SERMs based on the dynamics of estrogen receptor transcriptional activity in living animals.
Topics: Animals; Blotting, Western; Estradiol; Estrogens, Conjugated (USP); Female; Indoles; Mice; Mice, Inbred C57BL; Ovariectomy; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Transcription, Genetic | 2010 |
Third-generation SERMs may face uphill battle.
Topics: Anticarcinogenic Agents; Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Drug Industry; Estradiol; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Patents as Topic; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; United States; United States Food and Drug Administration | 2010 |
The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
Topics: Breast Neoplasms; Estrogen Antagonists; Estrogens; Female; Female Urogenital Diseases; Humans; Indoles; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes | 2011 |
Selective estrogen receptor modulators: the future in menopausal treatment.
Topics: Female; Forecasting; Humans; Indoles; Menopause; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes | 2011 |
In vitro bioactivation of bazedoxifene and 2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol in human liver microsomes.
Topics: Cytochrome P-450 Enzyme System; Glutathione; Humans; Indoles; Isoenzymes; Microsomes, Liver; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tandem Mass Spectrometry | 2012 |
Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women.
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Incidence; Indoles; Models, Economic; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Placebos; Raloxifene Hydrochloride; Risk Factors; Treatment Outcome | 2013 |
Cooperative activation of gene expression by agonists and antagonists mediated by estrogen receptor heteroligand dimer complexes.
Topics: Cell Line, Tumor; DNA; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Gene Expression; HeLa Cells; Hep G2 Cells; Humans; Indoles; Ligands; Mutation; Promoter Regions, Genetic; Protein Multimerization; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription, Genetic; Transcriptional Activation | 2013 |
Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.
Topics: Aged; Algorithms; Bone Density Conservation Agents; Cost-Benefit Analysis; Decision Support Techniques; Dose-Response Relationship, Drug; Europe; Female; Health Care Costs; Health Services Research; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality of Life; Raloxifene Hydrochloride; Risk Assessment; Sensitivity and Specificity | 2014 |
Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cytokine Receptor gp130; Drug Design; Drug Repositioning; Drug Screening Assays, Antitumor; Humans; Indoles; Interleukin-6; Ligands; Molecular Docking Simulation; Phosphorylation; Protein Interaction Domains and Motifs; Protein Multimerization; Raloxifene Hydrochloride; Signal Transduction; STAT3 Transcription Factor | 2014 |
SERMs attenuate estrogen-induced malignant transformation of human mammary epithelial cells by upregulating detoxification of oxidative metabolites.
Topics: Cell Transformation, Neoplastic; Cells, Cultured; Cytoprotection; Estradiol; Humans; Inactivation, Metabolic; Indoles; Mammary Glands, Human; MCF-7 Cells; Oxidants; Oxidative Stress; Piperidines; Raloxifene Hydrochloride; Reactive Oxygen Species; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Up-Regulation | 2014 |
Estrogen replacement therapy regulation of energy metabolism in female mouse hypothalamus.
Topics: Animals; Body Weight; Energy Metabolism; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Estrogens; Female; Hypothalamus; Indoles; Mice; Raloxifene Hydrochloride | 2014 |
Differential effects of selective estrogen receptor modulators on the vagina and its supportive tissues.
Topics: Animals; Collagen; Dose-Response Relationship, Drug; Estrogens, Conjugated (USP); Female; Indoles; Mammary Glands, Animal; Raloxifene Hydrochloride; Random Allocation; Rats; Selective Estrogen Receptor Modulators; Tamoxifen; Vagina | 2016 |
[Selective estrogen receptor modulators (SERMs)].
Topics: Bone Density; Female; Humans; Indoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators | 2015 |
Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis.
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Indoles; Male; Mice; Mice, Inbred C57BL; Orchiectomy; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Testosterone; Vitamin D | 2017 |
Bazedoxifene and raloxifene protect neocortical neurons undergoing hypoxia via targeting ERα and PPAR-γ.
Topics: Animals; Aromatase; Caspase 3; Cell Hypoxia; Cells, Cultured; Enzyme Activation; Estrogen Receptor alpha; Hippocampus; Indoles; L-Lactate Dehydrogenase; Membrane Potential, Mitochondrial; Mice; Neocortex; Neurons; Neuroprotective Agents; PPAR gamma; Raloxifene Hydrochloride; RNA, Messenger; RNA, Small Interfering | 2018 |
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Indoles; Ligands; MCF-7 Cells; Mutant Proteins; Mutation; Piperazines; Protein Binding; Protein Domains; Protein Structure, Secondary; Pyridines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen | 2018 |
An Approach for Using In Vitro and In Silico Data to Identify Pharmaceuticals with Potential (Anti-)Estrogenic Activity in Aquatic Vertebrates at Environmentally Relevant Concentrations.
Topics: Animals; Biological Assay; Environmental Exposure; Estradiol; Estrogens; Ethinyl Estradiol; Fishes; Indoles; Pharmaceutical Preparations; Raloxifene Hydrochloride; Receptors, Estrogen | 2019 |
SERMs (selective estrogen receptor modulator), acting as estrogen receptor β agonists in hepatocellular carcinoma cells, inhibit the transforming growth factor-α-induced migration via specific inhibition of AKT signaling pathway.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Estrogen Receptor beta; Estrogens; Gene Expression Regulation, Neoplastic; Humans; Indoles; Liver Neoplasms; Proto-Oncogene Proteins c-akt; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured | 2022 |
Bazedoxifene, a Postmenopausal Drug, Acts as an Antimalarial and Inhibits Hemozoin Formation.
Topics: Animals; Antimalarials; Female; Heme; Hemeproteins; Hemoglobins; Humans; Indoles; Malaria; Malaria, Falciparum; Male; Mice; Neoplasms; Osteoporosis, Postmenopausal; Plasmodium falciparum; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2022 |
Raloxifene and bazedoxifene as selective ALDH1A1 inhibitors to ameliorate cyclophosphamide resistance: A drug repurposing approach.
Topics: Aldehyde Dehydrogenase 1 Family; Aldehyde Dehydrogenase, Mitochondrial; Cyclophosphamide; Drug Repositioning; Humans; Molecular Docking Simulation; Neoplasms; Raloxifene Hydrochloride; Retinal Dehydrogenase | 2023 |